

determine how successfully it is reaching its goals—to facilitate and improve the quality of clinical research conducted within the division. In addition, the CEPI Program assessment will determine whether previously recommended improvements included in the DPIP assessment were

successfully incorporated into the policy rollout process. The results may be used as a model for policy development to facilitate compliance in reporting certain incidents and implementation in other National Institutes of Health (NIH) Institutes and Centers (ICs) and will be shared with all

interested divisions and institutes within the NIH. There are no plans to share this information with the public. OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 470.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Frequency of response	Average time per response	Annual hour burden
DAIDS staff surveys IC review .....	Webpage Study Details and Informed Consent DAIDS Staff screenshots.	100	1	5/60	8
DAIDS staff surveys .....	DAIDS Staff Survey screenshots .....	100	1	30/60	50
ER/ES—web surveys IC review .....	Webpage Study Details and Informed Consent for Extramural Researchers and External Stakeholders screenshots.	400	1	5/60	33
ER/ES—web surveys .....	Extramural Researcher External Stakeholder Survey screenshots.	400	1	30/60	200
DAIDS staff—web survey reminder ..	Reminder email to T2 web-survey participants.	100	1	5/60	8
ER/ES—web survey reminder .....	Reminder email to T2 web-survey participants.	400	1	5/60	33
DAIDS staff focus group IC review ...	DAIDS staff focus group consent form.	18	1	10/60	3
ER/ES—focus group IC review .....	Extramural researcher external stakeholders focus group consent form.	63	1	10/60	11
ER/ES—focus group .....	Incentive distribution log for focus group participants.	63	1	2/60	2
DAIDS staff focus groups .....	Focus group opening script and questions.	18	1	90/60	27
ER/ES—focus groups .....	Focus group opening script and questions.	63	1	90/60	95
Totals .....	.....	1162	.....	.....	470

Dated: September 12, 2014.  
**Dione Washington,**  
*Project Clearance Liaison, NIAID, NIH.*  
 [FR Doc. 2014-22306 Filed 9-18-14; 8:45 am]  
**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Call for Participation for Computational Photography Project for Pill Identification (C3PI)**

**ACTION:** Notice.

**SUMMARY:** The National Library of Medicine (NLM) invites pharmaceutical manufacturers, re-packagers, wholesalers, and retail and institutional pharmacies to submit prescription drug products for imaging as part of its Computational Photography Project for Pill Identification (C3PI). The NLM is developing the C3PI oral solid dosage formulations (OSDFs) collection as part of an initiative to build a reliable and

high-quality image catalog of all OSDF prescription products marketed in the United States. Such a resource can support a number of public safety initiatives, such as in poison control, emergency response, and reduction of medication errors.

**FOR FURTHER INFORMATION CONTACT:** Any question regarding this process or the Computational Photography Project for Pill Identification (C3PI) should be sent to: [splimage@nlm.nih.gov](mailto:splimage@nlm.nih.gov).

**SUPPLEMENTARY INFORMATION:** The Computational Photography Project for Pill Identification (C3PI) aims to develop information infrastructure and computational tools for identifying pills from digital photographs and associated data. As part of C3PI, the NLM has imaged and currently hosts a growing collection of more than 2,000 validated images of pharmaceutical OSDFs. High quality images of these products, photographed using visible spectrum macrophotography techniques, are available for public access through an Applications Programming Interface (API) [<http://RxImage.nlm.nih.gov/>].

These images are also displayed in several NLM drug applications, including RxNav [<http://rxnav.nlm.nih.gov/>] and Pillbox [<http://pillbox.nlm.nih.gov/>].

NLM assisted the FDA in the development the current SPLIMAGE file specification [<http://dailymed.nlm.nih.gov/dailymed/splimagespec.cfm>], which was published in 2012 for submitting image files of oral solid dosage forms to the Food and Drug Administration (FDA) with Structured Product Label (SPL) documents. As part of the ongoing initiative to improve access to quality drug information, the NLM has worked closely with FDA's Center for Drug Evaluation and Research and Office of the Commissioner to increase the number of SPLIMAGE files included in SPL submissions. C3PI has successfully produced more than 2,000 SPLIMAGE files and these SPLIMAGE files have been made available through an NLM portal: <http://SPLImage.nlm.nih.gov>.

NLM is seeking the collaboration of pharmaceutical manufacturers, re-

packagers, wholesalers and pharmacies to obtain physical samples of OSDF products whose origin can be traced back to pharmaceutical manufacturers or private label distributors registered or listed with the Food and Drug Administration (FDA). The NLM will produce SPLIMAGE files suitable for inclusion in submissions to the Food and Drug Administration's Structured Product Labeling (SPL) program [<http://www.fda.gov/forindustry/datastandards/structuredproductlabeling/default.htm>]. A secure online portal will be used to make SPLIMAGE files available to participants responding to this **Federal Register** notice.

C3PI will also support computer vision research. NLM computer scientists are seeking object identification metrics and methods that are invariant with respect to camera angle, lighting, and the color transfer functions often found in digital cameras. The comprehensive collection of images will serve as foundation for research in content-based information retrieval and image-based search in an area of healthcare that directly impacts public safety: Safe medication identification and management. In addition to image data, C3PI is generating information on color classification, image segmentation, pill description and dimensions, as well as other metadata.

C3PI is led and managed by NLM's Office of High Performance Computing and Communications in the Lister Hill National Center for Biomedical Communications. Additional information on NLM's Office of High Performance Computing and Communications is available at: <http://lhncbc.nlm.nih.gov/branch/office-high-performance-computing-and-communications>. Information on the Lister Hill National Center for Biomedical Communications is available at: <http://lhncbc.nlm.nih.gov/>.

### General Instructions for Participating in C3PI

To participate in C3PI please visit <http://SPLImage.nlm.nih.gov> and follow the specific instructions provided. General instructions follow below:

1. Pharmaceutical manufacturers, private label distributors, re-packagers, wholesalers, and retail or institutional pharmacies (Participants) interested in submitting OSDF products to be imaged as part of the NLM sponsored C3PI OSDF Imaging initiative must first communicate their intention to participate in the project by contacting the NLM Point-of-Contact (NLM-PoC) using one of the following means:  
Email: [splimage@nlm.nih.gov](mailto:splimage@nlm.nih.gov)

Or mail to: The National Library of Medicine, C3PI Imaging Initiative, Building 38A, Room B1N-30, 8600 Rockville Pike, Bethesda, MD 20894.

2. NLM-PoC will acknowledge the Participant's communication of intent and will provide the Participant with the necessary DEA and State Licensing documents to allow for the secure shipment of OSDF products to the NLM imaging facility.

3. Prior to shipping OSDFs to the NLM imaging facility, the Participant will provide the NLM-PoC a detailed and complete list of prescription drug products that they intend to submit to NLM for processing and imaging.

4. After the NLM-PoC has authorized the shipment of the prescription drug products in writing, the products will be sent to the address provided by the NLM-PoC. In order for NLM to accept the shipment, the participant *must* provide NLM-PoC with written confirmation for the shipment, including: (a) Shipping manifest details, (b) shipping service used, (c) tracking number, and (d) expected date of arrival.

5. NLM will have a licensed pharmacist review the received contents and match them against the shipment manifest provided the NLM-PoC. NLM-PoC will acknowledge receipt of shipment within 72hrs of its arrival at the appropriate location and will provide the Participant with an estimate of the date by which OSDF SPLIMAGE-candidate files will become available through the secure online portal: <http://SPLImage.nlm.nih.gov>.

### Previous NLM Imaging Initiative Superseded

This notice supersedes all prior instructions provided by 76 FR 29773–29775 <https://federalregister.gov/a/2011-12629>, published on May 23, 2011.

Dated: September 12, 2014.

**Betsy L. Humphreys,**

*Deputy Director, National Library of Medicine, National Institutes of Health.*

[FR Doc. 2014–22308 Filed 9–18–14; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Skeletal Biology.

*Date:* October 3, 2014.

*Time:* 11:30 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Torrance Marriott South Bay, 3635 Fashion Way, Torrance, CA 90503.

*Contact Person:* Aruna K Behera, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4211, MSC 7814, Bethesda, MD 20892, 301-435-6809, [beheraak@csr.nih.gov](mailto:beheraak@csr.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* Infectious Diseases and Microbiology Integrated Review Group, Virology—A Study Section.

*Date:* October 16–17, 2014.

*Time:* 8:30 a.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Admiral Fell Inn, 888 South Broadway, Baltimore, MD 21231.

*Contact Person:* Joanna M Pyper, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3198, MSC 7808, Bethesda, MD 20892, (301) 435-1151, [pyperj@csr.nih.gov](mailto:pyperj@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Drug Discovery and Mechanisms of Antimicrobial Resistance.

*Date:* October 16, 2014.

*Time:* 11:30 a.m. to 12:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Fouad A. El-Zaatari, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3186, MSC 7808, Bethesda, MD 20892, (301) 435-1149, [elzaataf@csr.nih.gov](mailto:elzaataf@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)